NattoPharma (OSL:NATTO) (Lysaker, Norway, 11 September 2008) NattoPharma ASA has entered into an exclusive distribution agreement with Pathway International Pty Ltd for the natural K2 vitamin product MenaQ7(TM) in Australia and New Zealand. The agreement is an important element in NattoPharma's strategy to ensure global distribution of MenaQ7(TM).
Pathway, which is based in Sydney, is a recognized distributor of quality ingredients in dietary supplements and pharmaceutical products. During the past few years, the company has introduced several ingredients in the Australian and NZ markets.
- MenaQ7 fits well with the portfolio of health products distributed by Pathway. The company has extensive experience from obtaining regulatory approval of new products and will be an important partner for NattoPharma in the process to obtain approval of the natural vitamin MenaQ7 in Australia, comments Siri Stabel Olsen, NattoPharma Vice President of Sales and Marketing.
The Norway-based NattoPharma is listed on the Oslo Axess list at the Oslo Stock Exchange and is an exclusive supplier of MenaQ7. NattoPharma has established an extensive research and development program aimed at documenting the benefits of the K2 vitamin as a dietary supplement and food ingredient. MenaQ7 is extracted from the Japanese soy bean natto.
Research shows that the vitamin K2 is essential to develop and maintain strong bones as well as to avoid calcium deposits in the arteries.
For further information, please contact Siri Stabel Olsen, ph. +47 99252274
www.nattopharma.com
www.pathway.net.au
LINK: http://hugin.info/137386/R/1250802/271807.pdf
NattoPharma
http://www.nattopharma.com
ISIN: NO0010289200
Stock Identifier: OSE.NATTO
Pathway, which is based in Sydney, is a recognized distributor of quality ingredients in dietary supplements and pharmaceutical products. During the past few years, the company has introduced several ingredients in the Australian and NZ markets.
- MenaQ7 fits well with the portfolio of health products distributed by Pathway. The company has extensive experience from obtaining regulatory approval of new products and will be an important partner for NattoPharma in the process to obtain approval of the natural vitamin MenaQ7 in Australia, comments Siri Stabel Olsen, NattoPharma Vice President of Sales and Marketing.
The Norway-based NattoPharma is listed on the Oslo Axess list at the Oslo Stock Exchange and is an exclusive supplier of MenaQ7. NattoPharma has established an extensive research and development program aimed at documenting the benefits of the K2 vitamin as a dietary supplement and food ingredient. MenaQ7 is extracted from the Japanese soy bean natto.
Research shows that the vitamin K2 is essential to develop and maintain strong bones as well as to avoid calcium deposits in the arteries.
For further information, please contact Siri Stabel Olsen, ph. +47 99252274
www.nattopharma.com
www.pathway.net.au
LINK: http://hugin.info/137386/R/1250802/271807.pdf
NattoPharma
http://www.nattopharma.com
ISIN: NO0010289200
Stock Identifier: OSE.NATTO
 |
Related Companies |
>>> NattoPharma |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 7 Days: 20) (Last 30 Days: 230) (Since Published: 7330) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
AJAX UNION |
|||
|
|||
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
